On target? Strategies and progress in the development of therapies for colorectal cancer targeted against WNT signalling

Colorectal Disease

Volumn 13, Issue 4, 2011, Pages 360-369

  Mcdonald, S L ^a   Silver, A R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

catenin; Cancer; Colorectal; Targeted therapy; WNT

Indexed keywords

BETA CATENIN; VASCULOTROPIN RECEPTOR; WNT PROTEIN;

CANCER CHEMOTHERAPY; CANCER GROWTH; COLORECTAL CANCER; GENETIC TRANSCRIPTION; METASTASIS; PRIORITY JOURNAL; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA CATENIN; COLORECTAL NEOPLASMS; GENE SILENCING; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; WNT PROTEINS;

EID: 79952503563     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2009.02149.x     Document Type: Review

References (94)

1. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000; 321: 531-5.
2. Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-9.
3. Kuebler JP, Wieand HS, O'Connell MJ et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198-204.
4. Kohne CH, van Cutsem E, Wils J et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856-65.
5. Arkenau HT, Arnold D, Cassidy J et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008; 26: 5910-7.
6. Mitry E, Rachet B, Quinn MJ, Cooper N, Coleman MP. Survival from cancer of the colon in England and Wales up to 2001. Br J Cancer 2008; 99(Suppl. 1): S26-9.
7. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31: 637-43.
8. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-8.
9. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
10. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65.
11. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-12.
12. Oliveira C, Pinto M, Duval A et al. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 2003; 22: 9192-6.
13. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005; 69(Suppl. 3): 11-6.
14. Ishigami SI, Arii S, Furutani M, Niwano M, Harada T, Mizumoto M, Mori A, Onodera H, Imamura M. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998; 78: 1379-84.
15. Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 2007; 8: 898-911.
16. Suraweera N, Robinson J, Volikos E, Guenther T, Talbot I, Tomlinson I, Silver A. Mutations within Wnt pathway genes in sporadic colorectal cancers and cell lines. Int J Cancer 2006; 119: 1837-42.
17. Simons M, Mlodzik M. Planar cell polarity signaling: from fly development to human disease. Annu Rev Genet 2008; 42: 517-40.
18. Blanpain C, Horsley V, Fuchs E. Epithelial stem cells: turning over new leaves. Cell 2007; 128: 445-58.
19. Barker N, van de Wetering M, Clevers H. The intestinal stem cell. Genes Dev 2008; 22: 1856-64.
20. Veeman MT, Axelrod JD, Moon RT. A second canon. Functions and mechanisms of β-catenin-independent Wnt signaling. Dev Cell 2003; 5: 367-77.
21. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003; 1653: 1-24.
22. Kikuchi A, Yamamoto H. Tumor formation due to abnormalities in the β-catenin-independent pathway of Wnt signaling. Cancer Sci 2008; 99: 202-8.
23. DasGupta R, Kaykas A, Moon RT, Perrimon N. Functional genomic analysis of the Wnt-wingless signaling pathway. Science 2005; 308: 826-33.
24. Tang W, Dodge M, Gundapaneni D, Michnoff C, Roth M, Lum L. A genome-wide RNAi screen for Wnt/β-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. Proc Natl Acad Sci USA 2008; 105: 9697-702.
25. Bilic J, Huang YL, Davidson G, Zimmermann T, Cruciat CM, Bienz M, Niehrs C. Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science 2007; 316: 1619-22.
26. Zeng X, Huang H, Tamai K et al. Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 2008; 135: 367-75.
27. Suzuki H, Watkins DN, Jair KW et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36: 417-22.
28. Chen L, Wang K, Shao Y, Huang J, Li X, Shan J, Wu D, Zheng JJ. Structural insight into the mechanisms of Wnt signaling antagonism by Dkk. J Biol Chem 2008; 283: 23364-70.
29. Winkel A, Stricker S, Tylzanowski P, Seiffart V, Mundlos S, Gross G, Hoffmann A. Wnt-ligand-dependent interaction of TAK1 (TGF-β-activated kinase-1) with the receptor tyrosine kinase Ror2 modulates canonical Wnt-signalling. Cell Signal 2008; 20: 2134-44.
30. Segditsas S, Sieber O, Deheragoda M et al. Putative direct and indirect Wnt targets identified through consistent gene expression changes in APC-mutant intestinal adenomas from humans and mice. Hum Mol Genet 2008; 17: 3864-75.
31. Vlad A, Rohrs S, Klein-Hitpass L, Muller O. The first five years of the Wnt targetome. Cell Signal 2008; 20: 795-802.
32. Kitaeva MN, Grogan L, Williams JP, Dimond E, Nakahara K, Hausner P, DeNobile JW, Soballe PW, Kirsch IR. Mutations in β-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors. Cancer Res 1997; 57: 4478-81.
33. -/- colon carcinoma. Science 1997; 275: 1784-7.
34. Batra S, Shi Y, Kuchenbecker KM et al. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun 2006; 342: 1228-32.
35. Dejmek J, Dejmek A, Safholm A, Sjolander A, Andersson T. Wnt-5a protein expression in primary Dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res 2005; 65: 9142-6.
36. Ying J, Li H, Yu J, Ng KM, Poon FF, Wong SC, Chan AT, Sung JJ, Tao Q. WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/β-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res 2008; 14: 55-61.
37. Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci USA 1996; 93: 7950-4.
38. Koinuma K, Yamashita Y, Liu W et al. Epigenetic silencing of AXIN2 in colorectal carcinoma with microsatellite instability. Oncogene 2006; 25: 139-46.
39. Dihlmann S, Siermann A, von Knebel Doeberitz M. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate β-catenin/TCF-4 signaling. Oncogene 2001; 20: 645-53.
40. Arber N, Eagle CJ, Spicak J et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885-95.
41. Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-90.
42. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603-13.
43. Arber N, Levin B. Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology 2008; 134: 1224-37.
44. s-axin-β-catenin signaling axis. Science 2005; 310: 1504-10.
45. Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, Iverson ER, Demets DL. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008; 372: 1756-64.
46. Buchanan FG, DuBois RN. Connecting COX-2 and Wnt in cancer. Cancer Cell 2006; 9: 6-8.
47. Dihlmann S, von Knebel Doeberitz M. Wnt/β-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer 2005; 113: 515-24.
48. He B, Reguart N, You L, Mazieres J, Xu Z, Lee AY, Mikami I, McCormick F, Jablons DM. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 2005; 24: 3054-8.
49. Fujii N, You L, Xu Z, Uematsu K, Shan J, He B, Mikami I, Edmondson LR, Neale G, Zheng J, Guy RK, Jablons DM. An antagonist of dishevelled protein-protein interaction suppresses β-catenin-dependent tumor cell growth. Cancer Res 2007; 67: 573-9.
50. Chen B, Dodge ME, Tang W et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009; 5: 100-7.
51. Park CH, Chang JY, Hahm ER, Park S, Kim HK, Yang CH. Quercetin, a potent inhibitor against β-catenin/Tcf signaling in SW480 colon cancer cells. Biochem Biophys Res Commun 2005; 328: 227-34.
52. Gwak J, Cho M, Gong SJ et al. Protein-kinase-C-mediated β-catenin phosphorylation negatively regulates the Wnt/β-catenin pathway. J Cell Sci 2006; 119:4702-9.
53. Emami KH, Nguyen C, Ma H et al. A small molecule inhibitor of β-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci USA 2004; 101: 12682-7.
54. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW, Shivdasani RA. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell 2004; 5: 91-102.
55. Easwaran V, Pishvaian M, Salimuddin, Byers S. Cross-regulation of β-catenin-LEF/TCF and retinoid signaling pathways. Curr Biol 1999; 9: 1415-8.
56. 3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of β-catenin signaling. J Cell Biol 2001; 154: 369-87.
57. Ordóñez-Morán P, Larriba MJ, Pálmer HG et al. RhoA-ROCK and p38MAPK-MSK1 mediate vitamin D effects on gene expression, phenotype, and Wnt pathway in colon cancer cells. J Cell Biol 2008; 183: 697-710.
58. Tan C, Costello P, Sanghera J, Dominguez D, Baulida J, de Herreros AG, Dedhar S. Inhibition of integrin linked kinase (ILK) suppresses β-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC-/- human colon carcinoma cells. Oncogene 2001; 20: 133-40.
59. Zhou L, An N, Haydon RC et al. Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the β-catenin signaling activity. Cancer Lett 2003; 193: 161-70.
60. You L, He B, Xu Z et al. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res 2004; 64: 5385-9.
61. Lee JH, Park CH, Jung KC, Rhee HS, Yang CH. Negative regulation of β-catenin/Tcf signaling by naringenin in AGS gastric cancer cell. Biochem Biophys Res Commun 2005; 335: 771-6.
62. Park CH, Hahm ER, Lee JH, Jung KC, Yang CH. Inhibition of β-catenin-mediated transactivation by flavanone in AGS gastric cancer cells. Biochem Biophys Res Commun 2005; 331: 1222-8.
63. Shan J, Shi DL, Wang J, Zheng J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 2005; 44: 15495-503.
64. Yasmin T, Takahashi-Yanaga F, Mori J, Miwa Y, Hirata M, Watanabe Y, Morimoto S, Sasaguri T. Differentiation-inducing factor-1 suppresses gene expression of cyclin D1 in tumor cells. Biochem Biophys Res Commun 2005; 338: 903-9.
65. Sukhdeo K, Mani M, Zhang Y et al. Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 2007; 104: 7516-21.
66. Mahindroo N, Punchihewa C, Bail AM, Fujii N. Indole-2-amide based biochemical antagonist of Dishevelled PDZ domain interaction down-regulates Dishevelled-driven Tcf transcriptional activity. Bioorg Med Chem Lett 2008; 18: 946-9.
67. Grandy D, Shan J, Zhang X et al. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J Biol Chem 2009; 284: 16256-63.
68. Bi X, Zhao Y, Fang W, Yang W. Anti-cancer bioactivities of Panax notoginseng extract 20(S)-25-OCH3-PPD: targeting β-catenin signaling. Clin Exp Pharmacol Physiol 2009; 36: 1074-8.
69. Zhang Y, Appleton BA, Wiesmann C, Lau T, Costa M, Hannoush RN, Sidhu SS. Inhibition of Wnt signaling by Dishevelled PDZ peptides. Nat Chem Biol 2009; 5: 217-9.
70. White AW, Westwell AD, Brahemi G. Protein-protein interactions as targets for small-molecule therapeutics in cancer. Expert Rev Mol Med 2008; 10: e8.
71. Firestein R, Bass AJ, Kim SY et al. CDK8 is a colorectal cancer oncogene that regulates β-catenin activity. Nature 2008; 455: 547-51.
72. Pannequin J, Delaunay N, Buchert M et al. β-Catenin/Tcf-4 inhibition after progastrin targeting reduces growth and drives differentiation of intestinal tumors. Gastroenterology 2007; 133: 1554-68.
73. Scoville DH, Sato T, He XC, Li L. Current view: intestinal stem cells and signaling. Gastroenterology 2008; 134: 849-64.
74. Kaiser S, Park YK, Franklin JL et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 2007; 8: R131.
75. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR, Vass JK, Athineos D, Clevers H, Clarke AR. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007; 446: 676-9.
76. Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 1997; 94: 1402-7.
77. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-9.
78. Nateri AS, Spencer-Dene B, Behrens A. Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature 2005; 437: 281-5.
79. Zimmermann S, Kiefer F, Prudenziati M, Spiller C, Hansen J, Floss T, Wurst W, Minucci S, Göttlicher M. Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res 2007; 67: 9047-54.
80. Min/+ mice due to decreases in c-Myc expression. Mol Cancer Res 2007; 5: 1296-303.
81. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-92.
82. Chau I, Rigg A, Cunningham D. Matrix metalloproteinase inhibitors - an emphasis on gastrointestinal malignancies. Crit Rev Oncol Hematol 2003; 45: 151-76.
83. Wagenaar-Miller RA, Gorden L, Matrisian LM. Matrix metalloproteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Rev 2004; 23: 119-35.
84. Overall CM, Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 2006; 94: 941-6.
85. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004; 5: 455-63.
86. Huang X, Guo B. Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer Res 2006; 66: 9245-51.
87. Atmaca A, Al-Batran SE, Maurer A et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007; 97: 177-82.
88. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008; 34: 206-22.
89. Prasad CP, Gupta SD, Rath G, Ralhan R. Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between β-catenin, dishevelled and cyclin D1 expression. Oncology 2007; 73: 112-7.
90. Rivera MN, Kim WJ, Wells J et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 2007; 315: 642-5.
91. Malanchi I, Peinado H, Kassen D et al. Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling. Nature 2008; 452: 650-3.
92. Major MB, Roberts BS, Berndt JD et al. New regulators of Wnt/β-catenin signaling revealed by integrative molecular screening. Sci Signal 2008; 1: ra12.
93. Le NH, Franken P, Fodde R. Tumour-stroma interactions in colorectal cancer: converging on β-catenin activation and cancer stemness. Br J Cancer 2008; 98: 1886-93.
94. Fodde R, Brabletz T. Wnt/β-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007; 19: 150-8.